CD274 and nasopharyngeal carcinoma: In the phase Ib study Keynote-028, 27 patients with PD-L1 positive R/M NPC received pembrolizumab; the majority of patients had been treated with prior therapies for advanced disease (range: 1–5 lines of treatment), whereas 2 patients received pembrolizumab as first line treatment [10].